Description: Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, antacid, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, gynecology, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services; and develops and out-licenses patented products. The company was incorporated in 1992 and is headquartered in Mumbai, India.
Home Page: www.marksanspharma.com
Grandeur
Mumbai,
400053
India
Phone:
91 22 4001 2000
Officers
| Name | Title |
|---|---|
| Mr. Mark B. Saldanha | Chairman, MD & CEO |
| Mr. Jitendra M. Sharma | Chief Financial Officer |
| Mr. Supratika Tripathi | Director of Operations |
| Mr. Bharatrajan Ramaswami | Chief Scientific Officer |
| Mr. Harshavardhan Panigrahi | Company Sec., Mang. of Legal & Compliance Officer |
| Ms. Sandra Saldanha | Whole-Time Director |
| Mr. Varddhman Vikramaditya Jain | Whole-Time Director |
| Mr. Sunil K. Rane | Sr. VP of QC |
| Mr. Sopan Pisal | Director of QA |
| Mr. Sridhar Naidu | Gen. Mang. of HR & Admin |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 12.051 |
| Price-to-Book MRQ: | 2.7521 |
| Price-to-Sales TTM: | 1.5287 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1150 |